|
?:authorAffiliation
|
-
[\'Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. kevin.saunders@duke.edu.\', \'Department of Surgery, Duke University, Durham, NC, USA. kevin.saunders@duke.edu.\', \'Department of Immunology, Duke University School of Medicine, Durham, NC, USA. kevin.saunders@duke.edu.\', \'Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA. kevin.saunders@duke.edu.\', \'Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.\', \'Department of Medicine, Duke University School of Medicine, Durham, NC, USA.\', \'Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.\', \'Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.\', \'Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, NC, USA.\', \'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Silver Spring, MD, USA.\', \'Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.\', \'Corporate Research Materials Lab, 3M Company, St Paul, MN, USA.\', \'Infectious Disease Research Institute, Seattle, WA, USA.\', \'Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.\', \'Department of Surgery, Duke University, Durham, NC, USA.\', \'BIOQUAL, Rockville, MD, USA.\', \'Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. barton.haynes@duke.edu.\', \'Department of Immunology, Duke University School of Medicine, Durham, NC, USA. barton.haynes@duke.edu.\', \'Department of Medicine, Duke University School of Medicine, Durham, NC, USA. barton.haynes@duke.edu.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}